Tangram to Present TGM-148 Data at ASH
Tangram Therapeutics will present preclinical data on its ZPI-silencing candidate TGM-148 at the ASH 2026 Annual Meeting in December.
Updated on Nov. 4, 2026 in Biotech
Tangram Therapeutics will present preclinical data for TGM-148, a GalNAc-conjugated siRNA that silences Protein Z-dependent Protease Inhibitor, in an oral session at the ASH 68th Annual Meeting in New Orleans on December 14, 2026. The company says TGM-148 showed efficacy across four distinct genetic disease models.
Why it matters
TGM-148 is designed as a subcutaneous therapy to regulate coagulation, with a target of four or fewer doses a year. The data will be a key step toward initial Phase 1 results anticipated in 2027.
The preclinical evidence comes from non-human primate plasma and repeat-dose toxicology studies, showing dose-dependent thrombin enhancement only in factor VIII-depleted plasma and good tolerability at the highest dose tested. Human relevance remains unproven, and the Phase 1 results that would test it are not expected until 2027.
The players
Tangram Therapeutics
Tangram Therapeutics is a London-based biotechnology company developing RNA-based therapies, including the ZPI-silencing candidate TGM-148.
American Society of Hematology (ASH)
The American Society of Hematology is a leading professional organization for blood disorder researchers and clinicians, whose annual meeting is among the field's largest scientific gatherings.
The details
Tangram will present the preclinical findings in an oral session on December 14, 2026, from 14:45 to 16:15 at the ASH meeting in New Orleans. TGM-148 is administered subcutaneously and was well tolerated up to the highest dose in healthy non-human primates, and a Phase 1 trial in healthy volunteers is already underway.
Timeline
December 12-15, 2026: ASH 68th Annual Meeting takes place in New Orleans, Louisiana.
December 14, 2026: Oral session on TGM-148 data, 14:45-16:15 local time.
2027: Initial Phase 1 trial data anticipated.
Big Picture
TGM-148 applies the GalNAc-conjugated siRNA platform, which delivers gene silencers selectively to liver cells, to a coagulation regulator rather than the metabolic targets more common in that field. The approach aims to offer prophylaxis for clotting disorders with a less frequent injection schedule than current options.
If TGM-148 reaches patients, it could offer protection against clotting disorders with four or fewer subcutaneous doses a year, rather than more frequent treatment. Those benefits remain hypothetical until human trial data are available in 2027.
The takeaway
Preclinical findings are a starting point, and readers should watch for the 2027 Phase 1 results before drawing conclusions about TGM-148's human safety or efficacy. The ASH presentation on December 14 will offer the first detailed look at the underlying data.
What happens next
Tangram will present TGM-148 data at the ASH 68th Annual Meeting on December 14, 2026, and initial Phase 1 trial data are anticipated in 2027.
Further reading
Explore more [biotech] coverage to see how RNA-based therapies are advancing toward the clinic.
More information
Learn more on the Tangram Therapeutics company website.
